Porton Advanced Secures License for Class C Drug Manufacturing

Porton Advanced Solutions Ltd. has officially obtained a Class C Drug Manufacturing License from China's National Medical Products Administration (NMPA). This regulatory approval allows the company to expand its contract development and manufacturing (CDMO) services beyond clinical trial materials into commercial-scale drug production.

The acquisition of the Class C license signifies a critical advancement for Porton Advanced, demonstrating the NMPA's confidence in the company's manufacturing processes and quality control systems. Previously, the company's focus was primarily on early-stage drug development and manufacturing for clinical studies.

With the ability to undertake commercial manufacturing, Porton Advanced can now support pharmaceutical clients throughout the entire product lifecycle, from development through to market launch. This expanded capability enhances the company's position as a global CDMO provider and offers significant value to clients seeking a comprehensive partner for their drug manufacturing needs.

The new license is expected to bolster Porton Advanced's competitive edge and create new business opportunities, particularly within the Chinese domestic market and internationally.